T1	Participants 194 264	patients with unresectable stage IIIA and B non-small-cell lung cancer
T2	Participants 447 637	Eligible patients were treatment naive, and had stage IIIA and B unresectable non-small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and normal organ function
T3	Participants 890 1072	A total of 388 patients were needed to detect a 50% increase in median survival from 14 months of qdRT to 21 months of HART; accrual was not achieved and the study closed prematurely
T4	Participants 1082 1187	Of 141 patients enrolled, 83% were randomly assigned after chemotherapy to qdRT (n = 59) or HART (n = 60)
